MODERNA INC (MRNA) 174.615 -1.73 (-0.98%)
174.615 -1.73 (-0.98%)
US60770K1079 - Common Stock
MODERNA INC174.615
NASDAQ:MRNA (2/3/2023, 12:48:08 PM)-1.73 (-0.98%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | 11-03 2022-11-03/bmo | Earnings (Next) | 02-22 2023-02-22 |
| Ins Owners | 5.42% | Inst Owners | 63.95% |
| Market Cap | 67.08B | Shares | 384.18M |
| PE | 6.32 | Fwd PE | 32.52 |
| Dividend Yield | N/A | Analysts | 74.62 |
| IPO | 12-07 2018-12-07 | ||
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 2,700 full-time employees. The company went IPO on 2018-12-07. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The company is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The firm develops technologies that enable the development of mRNA medicines for diverse applications. The company has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The firm develops technologies that enable the development of mRNA medicines.
Company Info
MODERNA INC
200 Technology Sq
Cambridge MASSACHUSETTS 02139
P: 16177146500.0
CEO: Stephane Bancel
Employees: 2700
Website: https://www.modernatx.com/
MRNA News
3 minutes ago - The Motley Fool3 No-Brainer Growth Stocks to Buy in 2023These stocks all fell by double digits last year.
5 hours ago - Personalis, Inc.Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
6 hours ago - The Motley FoolIs Moderna Stock a Buy Now?The company is starting the year on a strong note.
a day ago - InvestorPlaceThe 7 Most Undervalued Biotech Stocks to Buy in February 2023Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.
a day ago - Market News VideoMRNA March 24th Options Begin Trading
2 days ago - InvestorPlaceThe 7 Most Undervalued Nasdaq Stocks to Buy in February 2023For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.
MRNA Twits
Here you can normally see the latest stock twits on MRNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
